Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-CD19CD20-ALLO1 |
Synonyms | |
Therapy Description |
Limited information is currently available on P-CD19CD20-ALLO1, a putative allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (Aug 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-CD19CD20-ALLO1 | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 | Limited information is currently available on P-CD19CD20-ALLO1, a putative allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (Aug 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |